Evolving Therapeutic Landscape in T-Cell Lymphomas: Focus on EZH1/2 Inhibitors

Join us in Chicago or via simulcast for this 1.5-hour live, interactive CPE-certified program led by Steven M. Horwitz, MD, Pierluigi Porcu, MD, and Pamela B. Allen, MD discussing the rationale, evidence, and strategies with using EZH1/2 Inhibitors in patients with peripheral T-cell lymphomas.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

Agenda

Mechanism of Action of EZH1 and EZH2

  • Canonical mechanism
  • Noncanonical mechanism

Anti-EZH1 and EZH2 Therapies in PTCL and Beyond

  • Rationale for targeting EZH1/2 separately and in combination
  • Development in PTCL and other hematological malignancies

Clinical Trial Evidence of the Use of Anti-EZH1/2 Therapies in PTCL

  • Phase II VALENTINE-PTCL01
  • Safety and tolerability trials

Identifying and Managing Adverse Events

  • AEs associated with EZH1/2 therapies
  • Supportive strategies for managing AEs associated with EZH1/2 therapies

Faculty

Faculty
Pamela B. Allen, MD

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Faculty
Steven M. Horwitz, MD

Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York

Faculty
Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in understanding and integrating the latest science and clinical trial data on current and emerging anti-EZH1/2 therapies into treatment plans for patients with PTCL.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with PTCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the mechanism of action of EZH1 and EZH2 inhibitors and the rationale for their use in PTCL
  • Explain emerging clinical trial evidence of the use of anti-EZH1/2 therapies in PTCL
  • Identify adverse events associated with anti-EZH1/2 therapies to implement supportive management strategies
  • Incorporate new data into clinical practice and identify patients eligible for clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.